Table 2. Subgroup analyses for circulating adiponectin and endometrial cancer risk.

	No. of studies	RR (95% CI)	P(Z)	I 2	P(Q)	Reference
Overall	11	0.47 (0.33–0.66)	<0.001	67.5%	0.001	[11–21,30]
District
Asia	3	0.54 (0.37–0.80)	0.002	0.0%	0.943	[17,18,21]
Europe	3	0.31 (0.13–0.73)	0.007	70.2%	0.035	[11,13,15]
North-America	5	0.51 (0.27–0.95)	0.034	82.6%	<0.001	[12,14,16,19,20]
Menopausal status
Pre	3	0.92 (0.45–1.87)	0.807	29.1%	0.244	[11,13,19]
Post	7	0.50 (0.33–0.76)	0.001	53.8%	0.043	[11,13,15,16,18–20]
Combined	4	0.34 (0.18–0.66)	0.001	72.8%	0.012	[12,14,17,21]
Adjustment factors
Age
Yes	7	0.34 (0.21–0.54)	<0.001	64.8%	0.009	[11,12,14,15,17,18,21]
No	4	0.71 (0.47–1.07)	0.099	53.9%	0.089	[13,16,19,20]
BMI
Yes	9	0.45 (0.28–0.73)	0.001	73.7%	<0.001	[11–13,15,17–21]
No	2	0.47 (0.35–0.64)	<0.001	0.0%	0.948	[14,16]
hypertension
Yes	5	0.35 (0.16–0.74)	0.006	73.3%	0.010	[12,14,18,21]
No	6	0.54 (0.36–0.81)	0.002	64.2%	0.010	[11,13,15–17,19,20]
diabetes
Yes	5	0.44 (0.22–0.91)	0.027	78.4%	0.001	[12,16,18,19]
No	6	0.48 (0.33–0.71)	<0.001	58.8%	0.033	[11,13–15,17,20]

RR, relative risk; CI, confidence interval; pre, premenopause; post, postmenopause; BMI, body mass index.